Trodelvy (sacituzumab govitecan-hziy)
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for Trodelvy (sacituzumab govitecan-hziy), covering 2025-09-30 to 2026-01-20. Get the full timeline:
Most recent: Clinical Trial Update: Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) [Phase 3]